<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ISONIAZID</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ISONIAZID</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg daily for 6 months (initial and continuation phases).</li>
              <li class="dose child"><strong>For children </strong><br/>
                10 mg/kg once daily (max. per dose 300 mg) for 6 months (initial and continuation phases).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases).</li>
              <li class="dose child"><strong>For children </strong><br/>
                15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg daily for 6 months, alternatively 300 mg daily for 3 months, to be taken in combination with rifampicin.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                10 mg/kg daily (max. per dose 300 mg) for 6 months, alternatively 10 mg/kg daily (max. per dose 300 mg) for 3 months, to be taken in combination with rifampicin.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300 mg daily for 6 months, alternatively 300 mg daily for 3 months, to be taken in combination with rifampicin.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful; prophylactic pyridoxine recommended.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Risk of ototoxicity and peripheral neuropathy; prophylactic <xref format="dita" href="#PHP6206" type="drug" namespace="/drugs/pyridoxine-hydrochloride">pyridoxine hydrochloride</xref> recommended.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Drug-induced liver disease</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Peripheral neuropathy,
              </p>
              <p>
                <strong>rare:</strong> Hepatitis, psychotic episodes,
              </p>
              <p>
                <strong>notKnown:</strong> Agranulocytosis, aplastic anaemia, blood disorders, constipation, convulsions, difficulty with micturition, dry mouth, fever, gynaecomastia, haemolytic anaemia, hearing loss (in patients with end-stage renal impairment), hyperglycaemia, hyperreflexia, hypersensitivity reactions, interstitial pneumonitis, nausea, optic neuritis, pancreatitis, pellagra, peripheral neuritis with high doses, purpura, Stevens-Johnson syndrome, systemic lupus erythematosus-like syndrome, tinnitus (in patients with end-stage renal impairment), vertigo, vomiting,
              </p>
        
        
            <section class="advice">
              <h3 class="specificity">In adults</h3>
                <p class="title">Hepatitis</p>
              <p>Hepatitis more common in those aged over 35 years.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Hepatic disorders</h3>
              <p>Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Isoniazid for latent tuberculosis</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/isoniazid-for-latent-tuberculosis">www.medicinesforchildren.org.uk/isoniazid-for-latent-tuberculosis</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Isoniazid for treatment of tuberculosis</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk//isoniazid-for-the-treatment-of-tuberculosis">www.medicinesforchildren.org.ukisoniazid-for-the-treatment-of-tuberculosis</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            alcohol dependence
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            epilepsy
          </li>
          <li>
            history of psychosis
          </li>
          <li>
            HIV infection
          </li>
          <li>
            malnutrition
          </li>
          <li>
            slow acetylator status (increased risk of side-effects)
          </li>
        </ul>
        <ul>
          <li>
            <p>Peripheral neuropathy is more likely to occur where there are pre-existing risk factors such as diabetes, alcohol dependence, chronic renal failure, pregnancy, malnutrition and HIV infection. In patients at increased risk of peripheral neuropathy, <xref format="dita" href="#PHP6206" type="drug" namespace="/drugs/pyridoxine-hydrochloride">pyridoxine hydrochloride</xref> should be given prophylactically from the start of treatment.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>
            <i>Renal function</i> should be checked before treatment.</p><p>
            <i>Hepatic function</i> should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">In adults</h3>
              <p>Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>In general, doses should be rounded up to facilitate administration of suitable volumes of liquid or an appropriate strength of tablet.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">In children</h3>
              <p>Doses may need to be recalculated to allow for weight gain in younger children.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ISONIAZID</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP75047"><a href="../medicinalForm/PHP75047.html" data-target="#PHP75047" data-action="load">Tablet</a></div>
            <div id="PHP75055"><a href="../medicinalForm/PHP75055.html" data-target="#PHP75055" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
